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Background: Nanoparticles have become a key technology in multiple industries. However, there are growing
reports of the toxicity of nanomaterials to humans. In particular, nanomaterials have been linked to lung diseases.
The molecular mechanisms of nanoparticle toxicity are largely unexplored.
Methods: Acute lung injury was induced in wild-type mice and angiotensin-coverting enzyme 2 (ACE2) knockout
mice by the intratracheal instillation of cationic polyamidoamine dendrimer (PAMAM) nanoparticles. For rescue
experiments, losartan (15 mg/kg in PBS) was injected intraperitoneally 30 min before nanoparticle administration.
Results: Some PAMAM nanoparticles, but not anionic PAMAM nanoparticles or carbon nanotubes, triggered acute
lung failure in mice. Mechanistically, cationic nanoparticles can directly bind ACE2, decrease its activity and
down-regulate its expression level in lung tissue, resulting in deregulation of the renin-angiotensin system. Gene
inactivation of Ace2 can exacerbate lung injury. Importantly, the administration of losartan, which is an angiotensin
II type I receptor antagonist, can ameliorate PAMAM nanoparticle-induced lung injury.
Conclusions: Our data provide molecular insight into PAMAM nanoparticle-induced lung injury and suggest
potential therapeutic and screening strategies to address the safety of nanomaterials.
Keywords: Nanoparticles, Angiotensin II, Angiotensin-converting enzyme 2, Acute lung injury, LosartanBackground
Nanoparticles have become key materials in the pharma-
ceutical, information, and communication industries as
well as in multiple other areas that require strong, light
materials [1]. However, several concerns have been
raised about the safety of the widespread use of nanopar-
ticles [2,3]. Among these concerns, the potential toxicity
of nanoparticles to humans is among the most distres-
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unless otherwise stated.the cellular, subcellular, and protein levels, and they have
been found to elicit injurious responses in various or-
ganisms [4-6]. Many of these studies have focused on
lung diseases, including clinical studies of workers who
developed pulmonary disease from nanoparticle expos-
ure [7-11]. A worldwide moratorium on nanomaterials
has even been called until the safety issues have been re-
solved [12]. Nanoparticle safety in the respiratory system
is important not only for workers who have high expos-
ure to the particles but also in pulmonary drugs where
nanoparticles serve as a vehicle directly to the lung [13].
Therefore, it is of critical importance to elucidate the
molecular mechanisms by which nanoparticles induce
lung injury.
Polyamidoamine (PAMAM) dendrimers are a family of
dendritic polymers that are based on an ethylenediamineis is an Open Access article distributed under the terms of the Creative
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iginal work is properly credited. The Creative Commons Public Domain
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dendrimers grow through generations 1–10 (G1-G10, G
represents the generation of the dendrimers, which are
based on an ethylenediamine core and repeated amido-
amine branching), their size increases from 1.1–12.4 nm
[14,15]. PAMAM dendrimers are commercially available
as either whole (cationic) or half (anionic) generation poly-
mers. The low polydispersity index and the ability to pre-
cisely control their surface chemistry make dendrimers
useful for biomedicine applications such as drug or gene
delivery and diagnostic imaging [6,14]. For example,
PAMAM dendrimers can be used to inhibit inflammation
[16], improve therapeutic responses against cancer [17],
and suppress HIV-1 infection [18]. In addition, PAMAM
dendrimers can also be used as nanocarriers for pul-
monary drug delivery [19,20] or as an effective vector for
pulmonary gene transfer [21]. Because many PAMAM
nanoparticles have been considered carriers for pulmonary
drug delivery, in addition, a study reported that the
PAMAM can be found in major organs and have highest
levels in lungs in B16 melanoma and DU145 human
prostate cancer mouse tumor model [22], the safety of
PAMAM nanoparticles should be under rigorous as-
sessment and evaluation [23].
Previous reports have indicated that PAMAM dendri-
mers are toxic, and their toxicity is significantly influ-
enced by size and surface charge [24]. Specifically, the
charge of nanoparticles can also affect the oral toxicity
of PAMAM dendrimers [25]. Furthermore, PAMAM
dendrimers have been demonstrated to aggressively initi-
ate blood clot formation and disrupt key platelet func-
tions [26,27]. Although the systemic and oral toxicity of
PAMAM nanoparticles has been investigated, there are
few studies that have focused on the safety of PAMAM
nanoparticles in the respiratory system. Considering the
potential biomedical applications of PAMAM nanoparti-
cles, especially the applications in pulmonary disease, it
is paramount to investigate the underlying molecular
mechanisms that may be involved in PAMAM-induced
lung injury in vivo.
Results
G5 of PAMAM nanoparticles induce acute lung injury in
mice
To determine whether PAMAMs can induce lung injury
in mice, we tested different generations of PAMAMs via
intratracheal administration (15 μg/g) approach in vivo
(Detailed physical-chemical characteristic of PAMAMs
used in this study were list in Additional file 1: Table S1).
The G4, G5, G6, and G7 PAMAM dendrimers induced se-
vere lung injury, as evidenced by an increased wet-to-dry
weight ratio, which is a measure of lung edema and in-
flammation (Figure 1A). Among all of the tested nanopar-
ticles, high generations of cationic PAMAM nanoparticlesinduced severe alterations in the lungs, whereas low gen-
erations of PAMAM and carboxyl-terminated dendrimers
showed no acute toxicology; these results were consistent
with previous studies [24,26-29]. Because G5 PAMAM
nanoparticles (diameter is approximately 5 nm) exhibited
the most severe acute lung injury, we focused on the G5
PAMAM nanoparticles in subsequent experiments. We
also tested the acute toxicology of G5 PAMAM nanoparti-
cles in vivo; the result showed that the LD50 of the G5
PAMAM nanoparticle was 11.22 μg/g and the 95% confi-
dence limit was 9.89-12.74 μg/g (Table 1).
We first examined the survival rate of mice after the
administration of G5 PAMAM dendrimers to the lungs.
Almost all mice treated with G5 PAMAM nanoparticle
died within 48 hrs, whereas all control mice and mice
instilled with anionic G5.5 PAMAM dendrimers survived
(Figure 1B). The cause of death was rapid development of
severe lung injury characterized by decreased blood oxy-
genation (Figure 1C), increased lung tissue wet-to-dry
weight ratios (Figure 1D), and massively altered elastance
(Figure 1E). (Lung elastance is a measure of lung function,
i.e., the change in pressure per unit change in volume, and
indicates the stiffness of the lungs [30].) The histopath-
ology of G5 PAMAM-treated lungs showed increased
bleeding and inflammatory cell infiltration (Figure 1F).
Moreover, G5 PAMAM administration resulted in in-
creased vascular permeability (Figure 1G), another hall-
mark of acute lung injury/respiratory distress syndrome in
humans [31,32]. These results indicate that the inhalation
of G5 PAMAM nanoparticles induces acute lung injury in
mice, resulting in pathologies that resemble acute respira-
tory distress syndrome in humans.
ACE2 controls G5 PAMAM nanoparticle-induced lung injury
We previously discovered a role for ACE2 in protecting
mice from severe acute lung injury [33-35]. ACE2 pro-
teolytically cleaves angiotensin II (AngII) and thereby
negatively regulates the renin-angiotensin system (RAS)
[36]. The induction of acute lung injury by acid as-
piration, sepsis, or SARS-CoV resulted in the down-
regulation of ACE2 expression in mouse lung tissue and
the subsequent upregulation of AngII [33,34]. We also
reported that plasma AngII levels are linked to disease
severity and can predict fatal outcomes in H7N9-
infected patients [37]. We therefore tested whether the
RAS was also affected during nanoparticle-induced lung
injury in mice. The serum AngII levels were measured
in mice following the inhalation of PAMAMs, and other
nanomaterials (Figure 2A, Additional file 2: Figure S1A).
Additionally, ACE2 mRNA (Figure 2B) and protein levels
in the lungs were determined (Figure 2C, Additional file 2:
Figure S1B). The RAS system was markedly activated,
as demonstrated by the increased serum AngII levels in
mice treated with G4, G5, and G6 cationic PAMAM
Figure 1 (See legend on next page.)
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Figure 1 G5 PAMAM dendrimers induce severe acute lung injury. (A)Wet-to-dry weight ratios of the lungs after the administration of nanoparticles
(15 μg/g) at 10 hrs after administration. n = 4–6 mice per group. **p < 0.01 compared with the G4-, G5-, G6-, and G7-treated groups and the vehicle
control cohort using two-tailed t-test analysis. (B) Survival rates. n = 10 mice per group. **p < 0.01 for the comparison of the G5 group with either the
G5.5 or control group. (log-rank test). (C) Arterial blood partial oxygen pressure (PaO2) and (D) Lung wet-to-dry weight ratios 10 hrs after the intratracheal
instillation of the vehicle control, G5.5 (15 μg/g), or G5 (15 μg/g). n = 5 mice per group. **p < 0.01 for the comparison of the G5-treated cohorts with the
G5.5-treated and control groups. (two-tailed t-test). (E) Change in lung elastance following a challenge with nanoparticles (15 μg/g) or the vehicle.
n = 5–6 mice per group. (ANOVA with Bonferroni post-hoc analysis). (F) Representative images of lung pathology 10 hrs after the administration of the
vehicle control or G5.5 or G5 nanoparticles (15 μg/g). The mean number of infiltrating cells per microscopic field ± SEM is also shown. n = 100 fields
analyzed for three mice for each treatment group. (two-tailed t-test). Scale bar = 100 μm. (G) Representative images of lungs injected with Evans blue
10 hrs after challenge with nanoparticles (15 μg/g) or the vehicle (control). The amount of extravascular Evans blue was determined 10 hrs after the
injection of nanoparticles or vehicle. n = 4–5 mice per group. (two-tailed t-test). Data are shown as the mean values ± SEM, except the survival curve.
*p< 0.05 or **p < 0.01.
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effect (Figure 2A). Moreover, the inhalation of G5 and
G6 PAMAM dendrimers resulted in significant down-
regulation of ACE2 protein expression in lung tissue, again
with G5 PAMAM inducing the greatest effect (Figure 2C).
Inhalation of G4 and G7 PAMAM nanoparticles also re-
sulted in reduced ACE2 expression in the lungs, although
these differences did not reach statistical significance. Not-
ably, the lung levels of ACE, the enzyme that generates
AngII [38], were apparently not affected by PAMAM in-
halation (Figure 2C). Thus, the pulmonary administration
of certain PAMAM nanoparticles, especially G5 PAMAM,
markedly activate the RAS via the down-regulation of
ACE2 expression.
To further elucidate the mechanism of ACE2 down-
regulation, we first explored whether the loss of ACE2
activity was caused by the direct binding of ACE2 to nano-
particles. We assessed the binding affinity of ACE2 for vari-
ous nanoparticles using surface plasmon resonance (SPR).
Interestingly, most cationic PAMAMs could bind ACE2
protein directly, whereas the anionic PAMAMs failed to
bind ACE2 (Figure 2D, Additional file 3: Figure S2). This
is predictable since the theoretical isoelectric point of pro-
tein ACE2 calculated by Expasy (http://www.expasy.org) is
5.36 and the SPR assay is performed in neutral pH. The
dynamic binding constants and equilibrium dissociationTable 1 The result of acute toxicity of G5 PAMAM
nanoparticles in mice
Group Dose Animal number Number of
animals
Mortality Livability
(μg/g) (n) dead/dosed p q
I 0 6 0 0.00 1.00
II 7.35 6 1 0.17 0.83
III 10.5 6 2 0.33 0.67
IV 15 6 5 0.83 0.17
V 21.43 6 6 1.00 0.00
VI 30.61 6 6 1.00 0.00
The percent mortality was recorded at 48 hrs after treatment with G5
PAMAM nanoparticles.constants for the binding between the examined nanoparti-
cles and ACE2 were also measured, demonstrating that G5
PAMAM nanoparticles, in particular, strongly bind to
ACE2 (Additional file 4: Table S2). We next monitored
ACE2 enzyme activity by measuring AngII levels after mix-
ing recombinant ACE2 protein and various nanoparticles
in vitro. The enzymatic activity of ACE2 was decreased
after incubation with cationic G5 PAMAM nanoparticles,
but its activity was not affected after incubation with an-
ionic G5.5 PAMAM in vitro (Figure 2E). These data show
that G5 PAMAM nanoparticles can directly associate with
ACE2 and alter its enzymatic activity, thereby resulting in
activation of the RAS.
Finally, to determine whether ACE2 has a critical role in
the acute lung injury following G5 PAMAM dendrimer ad-
ministration, we examined mice that were genetically defi-
cient in Ace2 [36]. Following the administration of G5
PAMAM dendrimers, the Ace2-knockout mice died signifi-
cantly faster than the wild-type control mice (Figure 3A).
In addition, the G5 PAMAM-induced changes in lung elas-
tance, blood oxygenation, lung tissue wet-to-dry weight ra-
tio, and lung histopathology were exacerbated in Ace2-
knockout mice relative to Ace2-expressing control animals
(Figures 3B-E). These data indicate that G5 PAMAM den-
drimers can induce severe acute lung failure by functionally
altering the RAS, specifically via the down-regulation of
ACE2.
Losartan alleviates G5 PAMAM nanoparticle-induced lung
injury in mice
We next tested whether losartan, the first angiotensin re-
ceptor blocker (ARB) approved for clinical use, could res-
cue the severe lung injury that occurred following the
inhalation of G5 PAMAM dendrimers. Importantly, the ad-
ministration of losartan prolonged the overall survival time
of G5 PAMAM-treated wild type mice (Figure 4A), mark-
edly alleviated their impaired lung function (Figure 4B), at-
tenuated their increased AngII production (Figure 4C),
reduced the increased wet-to-dry weight ratio of their lung
tissue (Figure 4D), and improved the decreased blood oxy-
genation (Figure 4E). As measured by Evans blue vascular
Figure 2 (See legend on next page.)
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Figure 2 Down-regulated ACE2 expression in mice challenged with cationic PAMAM dendrimers. (A) Levels of AngII in the plasma of the
vehicle- (control) and nanoparticle-treated (15 μg/g) mice at 3 hrs after administration. AngII levels were determined using radioimmunoassays. n = 4–5
mice per group. *p < 0.05 or **p < 0.01 for the comparison of the G4, G5-, and G6-treated groups with the vehicle (control) group (two-tailed t-test).
(B) The ACE2 mRNA relative expression level of the vehicle- (control) and nanoparticle-treated (15 μg/g) mice at 3 hrs after administration. Data were
normalized to the expression of β-actin reference gene. (two-tailed t-test). (C) Western blots of total lung samples obtained 3 hrs after the instillation of
nanoparticles (15 μg/g). The blots are representative of three different mice for each treatment. Quantitative analyses of the ACE and ACE2 protein
levels are illustrated. The levels are shown as the mean ACE- and ACE2-to-β-actin ratios ± SEM. n = 3 mice per treatment. **p < 0.01 for the comparison
of the G5-, and G6-treated groups with the vehicle group (two-tailed t-test). (D) Binding of G5 and G5.5 nanoparticles to recombinant human ACE2 at
different concentrations was measured by surface plasmon resonance (SPR). The detailed dynamic binding constant and equilibrium dissociation
constant are shown in Table S2. (E) G5 and G5.5 nanoparticles at different concentrations were incubated with recombinant ACE2 and AngII. The levels
of AngII in the enzymatic activity measurement system were determined by radioimmunoassay. n = 3 tests per group. (two-tailed t-tests). Data are
shown as the mean values ± SEM. *p < 0.05 or **p < 0.01; N.S. means not significant.
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cular permeability of the pulmonary blood vessels in G5
PAMAM-treated mice (Figure 4F). In addition, treatment
with losartan ameliorated G5 PAMAM-induced lung his-
topathology, including bleeding and inflammation cell
infiltration (Figure 4G). Furthermore, we measured
interleukin-6 (IL-6), which was a classical pro-inflammatory
cytokine, in bronchoalveolar lavage fluid (BALF). Enzyme-
linked immuno sorbent assay (ELISA) result showed treat-
ment with losartan could reduce concentration of IL-6
in BALF after instillation of G5 PAMAM dendrimers.
(Figure 4H). Thus, nanoparticle-induced lung injury can
be inhibited by the administration of losartan.
Discussion
Since G5 PAMAM dendrimers can down-regulate the
expression of ACE2 in mRNA and protein levels signifi-
cantly after 3 hrs of instillation (Figure 2 B,C), and death
of mice occurred about 12 hours after instillation of
PAMAM G5 (Figure 1B), we choose time-point 10 hrs
after instillation of PAMAMs to evaluate the change of
lung function. Our data provide in vivo molecular
insight into the acute lung failure that can be induced by
nanomaterials. Our data indicate that G5 PAMAM den-
drimers down-regulate ACE2 expression in lung tissue,
resulting in increased AngII production and, conse-
quently, acute lung failure. Our SPR data show that
PAMAM G5 and protein ACE2 have the highest binding
affinity (Additional file 4: Table S2), however, PAMAM
G7 have the most amino surface groups (Additional file 1:
Table S1), suggesting that the nanoparticles surface charge
is not the only determinant. Further studies of conform-
ation characteristic and stability of PAMAM G5-ACE2
complex are needed.
In our study, PAMAM nanoparticles of G4-G7 could
induce lung edema (Figure 1A), whereas lower gener-
ation cationic and anionic PAMAM dendrimers exhib-
ited no acute lung toxicity. This result is consistent with
previous findings that state nanoparticle size significantly
influences the toxicology of PAMAM nanoparticles [24].
It is interesting to note that not all nanoparticles havesuch effects on the ACE2 and AngII levels; for example,
G5.5 PAMAM dendrimers appear to be less toxic than
G5 PAMAM dendrimers. Additional studies regarding
the entry of nanoparticles into pulmonary epithelial cells
and/or local resident macrophages are required to ex-
plain these differences. Nevertheless, minor modifica-
tions of nanomaterials appear to significantly reduce
their pulmonary toxicity, suggesting a possible approach
to enable a safer use of nanomaterials. We have previ-
ously shown that G3-8 cationic PAMAM nanoparticles,
COOH single-walled carbon nanotube, and copper oxide
nanoparticles induce autophagy in vitro in A549 cell
models or in vivo in mouse models [9,39,40]. Thus, the
severity of the lung injury triggered by PAMAM nano-
particles may be due to the activation of multiple signal-
ing pathways that collectively cause severe lung disease.
A previous study showed that AngII could increase au-
tophagy levels via activation of the AT1 receptor and
NADPH oxidase in vascular muscle cells [41]; whether
this signaling transduction pathway is involved in the
pathogenesis of lung failure induced by G5 PAMAM
nanoparticles needs further study. Our new data now
clearly establish that ACE2 and the RAS play key roles
in G5 PAMAM nanoparticle-induced lung injury. Inter-
estingly, these mechanisms also apply in severe acute
lung injury associated with acid aspiration, sepsis, or in-
fection with SARS-CoV, H5N1 and H7N9 influenza
[33-35,42]. Thus, these parallel mechanisms suggest that
ACE2 and RAS share a common disease mechanism for
acute lung injury and respiratory distress syndrome.
Modulating the RAS may have a wide range of thera-
peutic applications.
The development of nanotechnology has rapidly accel-
erated, with an estimated market of approximately one
trillion US dollars within the next few years [43]. Safety
problems associated with nanomaterials have recently
attracted attention, highlighting the urgent need for pro-
tocols that protect workers, consumers, and the environ-
ment [44]. We propose here a valuable strategy using
ARB drug to address potential acute lung injury might
be induced by application of PAMAMs.
Figure 3 (See legend on next page.)
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Figure 3 Ace2 deficiency increases the severity of G5 PAMAM nanoparticle-induced acute lung injury. (A) Survival rates of vehicle- (control) or
G5 PAMAM-treated (15 μg/g) wild-type (WT) and Ace2-knockout (ACE2 KO) mice. n = 10 mice per group. **p < 0.01 for the comparison of the WT + G5
group with the ACE2 KO +G5 group (log-rank test). (B) Percent changes in the lung elastance of the vehicle control and PAMAM G5-treated (15 μg/g)
WT and ACE2 KO mice at the indicated time points. n = 6 mice per group. **p < 0.01 for the comparison of the WT+ G5 group with the ACE2 KO + G5
group at the indicated time points. (ANOVA with Bonferroni post-hoc analysis). (C) PaO2 in the arterial blood of vehicle- (control) or G5 PAMAM-treated
(15 μg/g) WT and ACE2 KO mice. n = 4–7 mice per group. (two-tailed t-test). (D) Wet-to-dry weight ratios of the lungs of WT and ACE2 KO mice 10 hrs
after intratracheal instillation of vehicle (control) or G5 PAMAM (15 μg/g). n = 4 mice per group. (two-tailed t-test). (E) Representative lung pathologies
of WT and ACE2 KO mice 10 hrs after the administration of vehicle (control) or G5 PAMAM (15 μg/g). The numbers of infiltrating cells per microscopic
field ± SEM are also shown. n = 100 fields analyzed for three mice for each treatment. (two-tailed t-test). Scale bar = 100 μm. Data are shown as the
mean values ± SEM, except the survival curve. *p < 0.05 or **p < 0.01.
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We show that cationic PAMAM dendrimer nanoparticles
can trigger acute lung failure in mice. Mechanistically, cat-
ionic nanoparticles bind to ACE2 and down-regulate its
function and expression in lung tissue, resulting in deregu-
lation of the RAS. Importantly, the administration of
losartan ameliorated the nanoparticle-induced lung injury.
Our new insight into the molecular pathogenesis of
cationic PAMAM nanoparticle-induced lung failure
might therefore contribute to a better understanding of
nanoparticle toxicity and the development of improved
safety procedures for nanomaterials. Because ARB drugs
have a long historical application for hypertension, our
results not only uncover an important pathway of cat-
ionic PAMAM nanoparticle-induced lung toxicity, but
may allow translation of our findings to novel therapies
using classical ARB drugs.
Methods
Reagents
All PAMAM dendrimers, carbon nanotubes, and inorganic
nanoparticle powders were purchased from Sigma-Aldrich
PAMAM nanoparticles were air-dried on a super-clean
bench for 24 hrs to remove the methanol before an equal
volume of PBS was added to the tube. The samples were
mixed and stored at 4°C before use. The anti-ACE anti-
body (2E2) was purchased from Santa Cruz Biotechnology,
Inc. The anti-ACE2 antibody (clone 460502) and recom-
binant human ACE2 protein were purchased from R&D
systems. The anti-β-actin antibody (clone AC-15), angio-
tensin II (human), losartan and Evans blue were purchased
from Sigma-Aldrich. HS-PEG-COOH (Mw= 2000 Da),
HS-PEG-NH2 (Mw= 2000 Da), and HS-(CH2)11-EG6-
OH (Mw= 468 Da) were purchased from Shanghai Yare
Biotechnology, Inc. 1-(3-Dimethylaminopropyl)-3-ethyl-
carbodiimide hydrochloride (EDC), N-hydroxysuccinimide
(NHS), ethanol, NaOH, and ethanolamine were purchased
from Sigma-Aldrich. All these reagents were used without
further purification. Milli-Q water was obtained from a
Millipore − ELIX water purification system. All buffers
and reagents used were degassed and filtered prior to use
in the SPR experiments.Animals
All mice had a C57BL/6 J background. The development
of the Ace2-knockout mouse has been previously de-
scribed [36]. C57BL/6 J mice were purchased from Vital
River, Beijing. All mice were 4–6 weeks old. All animal
experiments were conducted in the animal facility at the
Institute of Basic Medical Sciences of the Peking Union
Medical College in accordance with local and institu-
tional guidelines.
Induction of lung injury
Lung injury was induced in mice by the intratracheal in-
stillation of nanoparticles at a concentration of 15 μg/g
using a technology that we have previously described for
SARS spike protein- and acid-induced lung injury [34].
For rescue experiments, losartan (15 mg/kg in PBS) was
injected intraperitoneally 30 min before nanoparticle
administration.
Acute toxicity study
A total of 48 male mice were divided into six groups of
six mice each and randomly allotted to the control and
G5 PAMAM nanoparticle groups. PBS was used in
Group I as a control. The mice in Groups II, III, IV, V
and VI were intratracheally injected with G5 PAMAM
nanoparticles with the concentration of 7.35, 10.5, 15,
21.43, 30.61 μg/g, respectively. The animals were ob-
served for 48 hrs after administration with nanoparticles
and the mortality rate was recorded. The LD50 value
(95% CL) was calculated using the improved Karber's
method. The LD50 was 11.22 μg/g and the 95% confi-
dence limit was 9.89-12.74 μg/g.
Assessment of pulmonary edema
Mice were instilled intratracheally with nanoparticles at
a concentration of 15 μg/g before assessing the extent of
pulmonary edema 10 hrs later when the lung wet-to-dry
weight ratios were calculated. In brief, after the blood
was drained from the excised lungs, the wet weight of
the lungs was measured. Lungs were then heated to 68°C
in an oven for 24 hrs and weighed to determine the base-
line dry mass of the lungs.
Figure 4 (See legend on next page.)
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Figure 4 Losartan reduces the severity of G5 PAMAM nanoparticle-induced acute lung injury. (A) Survival rates at indicated times (log-rank
test), (B) percent change in lung elastance at indicated times (ANOVA with Bonferroni post hoc analyses), (C) plasma AngII levels (at 3 hrs, two-tailed
t-tests), (D) lung wet-to-dry weight ratios (at 10 hrs, two-tailed t-tests), (E) blood oxygenation (at 10 hrs, two-tailed t-tests), (F) vascular leakage
(at 10 hrs, two-tailed t-tests), (G) histopathology, lung infiltrating cells counting (at 10 hrs) and (H) IL-6 concentration in BALF (at 10 hrs) of control
WT mice, WT mice treated with G5 PAMAM nanoparticles (15 μg/g), and WT mice treated with G5 PAMAM nanoparticles (15 μg/g) plus losartan
(15 mg/kg i.p.). n = 4–10 mice per group. (two-tailed t-tests). In (G), representative lung histopathologies and the mean numbers of lung-infiltrating
cells ± SEM per microscopic field (100 fields were analyzed; n = 3 mice per group) are shown. Scale bar = 100 μm. Data are shown as the mean
values ± SEM, except the survival curve. *p < 0.05 or **p < 0.01. N.D. means not detectable.
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Mice were intratracheally injected with either the vehicle
or nanoparticles (15 μg/g). The survival of each group was
recorded for 48 hrs and plotted using Kaplan-Meier sur-
vival curves. In the rescue group, losartan was intraperito-
neally injected 30 min before nanoparticle administration.
Assessment of blood oxygenation
Mice were intratracheally injected with nanoparticles at
a concentration of 15 μg/g. Ten hours later, blood sam-
ples were obtained from the common carotid artery, and
the PaO2 was measured (Radiometer ABL720 blood gas
analyzer, Diamond Diagnostics-USA) to assess arterial
blood oxygenation as an indicator of respiratory failure.
Lung elastance
Mice were anesthetized with sodium pentobarbital, and
then either the vehicle (control) or nanoparticles (15 μg/g)
dissolved in the same vehicle were administered intratra-
cheally. Lung elastance was then measured by BUXCO
Pulmonary Function Testing (PFT) every 30 min during
spontaneous breathing periods for 4 hrs. In the rescue
group, losartan (15 mg/kg) was intraperitoneally injected
30 min before nanoparticle administration.
Histopathology
Ten hours after the administration of nanoparticles
(15 μg/g), mice were sacrificed and their body weights de-
termined. The lungs were removed from the thoracic cavity
and placed in a glass vial containing approximately 50 mL
of fixative. Each glass vial was assigned a number unknown
to the pathologists. The lungs were fixed for at least 48 hrs
in formalin, embedded in paraffin, thin-sectioned coronally,
and mounted on glass slides using standard histopa-
thological techniques. The sections were stained with
hematoxylin and eosin. For each mouse, lung sections were
examined independently by three pathologists.
Pulmonary vascular permeability
Following the induction of lung injury, pulmonary vascu-
lar permeability was assessed by measuring the pulmonary
extravasation of Evans blue. Evans blue (20 μg/g) was
injected into the tail vein 10 hrs after the intratracheal in-
jection of nanoparticles. Ten minutes later, the animalswere sacrificed and their lungs were removed from the
thoracic cavity and perfused with ice-cold PBS via injec-
tion into the right ventricle. Then, the lung tissue was
immersed in formamide and analyzed to determine the
Evans blue content. The OD value of the Evans blue form-
amide solution was read using a microplate spectropho-
tometer at 620 nm. A standard concentration regression
curve was created and used to determine the level of
Evans blue in the lung tissue.Angiotensin II peptide levels
Mice were intratracheally injected with nanoparticles
(15 μg/g) and blood was collected 3 hrs later into 1.5 mL
tubes containing a mixture of peptidase inhibitors (0.30 M
ethylenediaminetetraacetic acid, 0.32 M dimercaprol, and
0.34 M 8-hydroxyquinoline sulfate). Radioimmunoassays to
determine the levels of angiotensin peptide in the plasma
extracts were performed as described previously [45]. In
the rescue group, losartan (15 mg/kg) was intraperitoneally
injected 30 min before nanoparticle administration.Real-time quantitative PCR analysis
For real-time quantitative PCR, lung tissue was obtained
3 hrs after the intratracheal injection of the nanoparticles
(15 μg/g) and then homogenized using TRIzol reagent
(Invitrogen). The RNA was extracted according to manu-
facturer’s instructions. Complementary DNA (cDNA) was
synthesized from 1.5 μg of total RNA with the High
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems). PCR amplification assays were performed with
the LightCycler 480 SYBR Green I Master (Roche Applied
Science) on a LightCycler 480 PCR System (Roche Applied
Science). PCR products were confirmed by sequencing.
Lung tissue samples were normalized to β-actin levels.
The specific primers used were listed as follows:
mouse β-actin forward primer: 5'- CTCTCCCTCAC
GCCATCC-3'
mouse β-actin reverse primer: 5'- CGCACGATTT
CCCTCTCAG-3'
mACE2 forward primer: 5'- GGCTACAACTATAAC
CGTAAC-3'
mACE2 reverse primer: 5'- TATCCATCAACTTCC
TCCTC-3'.
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Lung samples were obtained 3 hrs after the intratracheal
injection of the nanoparticles (15 μg/g) and homoge-
nized in ice-cold lysis buffer (50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 1.0% Triton X-100, 20 mM EDTA,
1 mM Na3VO4, 1 mM NaF, and protease inhibitors).
Tissue lysates were separated by SDS-PAGE and pro-
teins were transferred to NC membranes. The mem-
branes were incubated with antibodies to ACE, ACE2,
and β-actin, followed by incubation with a horseradish
peroxidase–conjugated secondary antibody. The band
intensity was analyzed using Quantity One software.
Surface plasmon resonance (SPR) experiments
To immobilize analytes with an amino terminus, HS-PEG-
COOH and HS-(CH2)11-EG6-OH (molar ratio, 1:10)
at a total concentration of 1 mM were printed on a
bare gold SPRi chip. To immobilize analytes with a
carboxyl terminus, HS-PEG-NH2 and HS-(CH2)11-
EG6-OH (molar ratio, 1:10) were printed on a bare gold
SPRi chip at a total concentration of 1 mM. Chips were in-
cubated in wet air at −4°C for 12 hrs to allow the forma-
tion of a uniform self-assembled mono-layer. Chips were
washed with deionized water and ethanol and dried in a
stream of N2. After activation with EDC/NHS for 10 min
(0.1 M NHS, 0.4 M EDC), 1 mg/mL analyte (G1, G2, G3,
G4, G5, G6, G7) was printed on the chip’s surface and the
chips were incubated for 2 hrs at −4°C. The un-reacted es-
ters were deactivated by exposing the chips to 1 M etha-
nolamine aqueous solution (pH = 8.5) for 10 min. For
carboxyl terminal analytes, the unreacted area of the SPRi
chip’s surface was deactivated by exposure to 1 M ethanol-
amine aqueous solution (including EDC/NHS solution)
for 30 min. The surface was washed with deionized water
and ethanol and then dried with nitrogen.
Real-time detection of protein adsorption was performed
using a Plexera Κχ5 V2 SPRi apparatus (Plexera Bioscience
LLC, USA). The entire SPRi chip surface was imaged dur-
ing the angular scan. The immobilized analyte spots with
100 μm diameters on the SPRi chip were selected. The
working optical position was automatically calculated ac-
cording to the plasma curve. The auto-injection system
controlled the flow at a rate of 2 μL⋅s−1. PBS (pH= 7.4) was
used as the running buffer. When baseline was obtained,
proteins at different concentrations (0.03 μM, 0.06 μM,
0.12 μM, and 0.23 μM) were injected into the flow cell.
NaOH (20 mM) was used as the regeneration solution. In
the kinetic analysis, the Plexera evaluation software was
used to fit the SPR curves to the Langmuir equation.
Enzymatic activity assays
Recombinant human ACE2 protein (20 ng/mL) was in-
cubated with or without 8 mg/mL different nanoparti-
cles (10 μL or 30 μL) at 37°C in assay buffer (75 mMTris, 1 M NaCl, pH = 7.5) for 10 min before adding
angiotensin II (400 pg/mL) for an additional 30 min at
37°C, except for the blank control sample. Radioimmu-
noassays to determine the level of angiotensin II peptide
in the assay buffer were performed as described previ-
ously [45].
Cytokine measurement
Bronchoalveolar lavage fluid (BALF) was obtained
10 hrs after the intratracheal injection of the nanoparti-
cles (15 μg/g). The concentration of IL-6 in the BALF
was determined by ELISA (R&D systems, DY406) ac-
cording to the manufacturer’s instructions. In the res-
cue group, losartan (15 mg/kg) was intraperitoneally
injected 30 min before nanoparticle administration.
Statistical analyses
All data are shown as the mean values ± SEM. Measure-
ments at single time points were analyzed by ANOVA,
and if they demonstrated significance, they were further
analyzed using a two-tailed t-test. Time courses were ana-
lyzed using repeated measures (mixed model) ANOVA
with Bonferroni post-hoc analyses. All statistical tests were
conducted using GraphPad Prism 5.0 (GraphPad Software,
San Diego, CA, USA). A value of p < 0.05 was used to indi-
cate statistical significance.
Additional files
Additional file 1: Table S1. Physical-chemical characteristics of
PAMAMs used in this study.
Additional file 2: Figure S1. Effects of various nanomaterials on ACE2
expression and plasma angiotensin II levels. (A)Plasma AngII levels of
mice receiving the vehicle (control) and mice instilled with the indicated
nanoparticles (all used at15 μg/g) at 3 hrs after challenge. n = 4 mice per
group. (B) ACE and ACE2 protein levels in lungs 3 hrs after the instillation
of t he indicated nanoparticles (15 μg/g). The upper panels show
representative Western blots. The bar graphs show ACE and ACE2 levels
as ratios to β-actin. n = 3 mice per group. Data are shown as the mean
values ± SEM. For A and B, no differences were detected between the
nanoparticle-treated groups and the vehicle control groups using two-tailed
t-tests.
Additional file 3: Figure S2. SPR signal of cationic polyamidoamine
dendrimer nanoparticles combined with ACE2. The binding abilities of
G2, G3, G4, G6 and G7 nanoparticles with recombinant ACE2 at different
concentrations were measured by surface plasmon resonance (SPR). The
detailed dynamic binding constants and equilibrium dissociation
constants are shown in Additional file 1: Table S1.
Additional file 4: Table S2. Kinetic parameters for the binding
between cationic polyamidoamine dendrimer nanoparticles and ACE2.
Binding of cationic polyamidoamine dendrimer nanoparticles, including
the cationic polymers G1, G2, G3, G4, G5, G6, and G7 and the
anionicpolymers G3.5, G4.5, G5.5, and G7.5, to recombinant ACE2 was
assessed using SPR. The detailed data for the ka (dynamic binding
constant), kd (dynamic dissociation constant), KA (equilibrium binding
constant) and KD (equilibrium dissociation constant) are indicated. N.D.
indicates that no SPR signal was detected.
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